Article Sidebar
Published:
May 10, 2016DOI:
10.4314/tjpr.v15i1.5Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Tricyclic Neovibsanin Scaffold Inhibits Glioma by Targeting Glioma-Initiating Cells
Abstract
Purpose: To investigate the effect of tricyclic neovibsanin scaffold (TCNS) on cell viability, colony formation capacity and induction of apoptosis in glioma cells.
Methods: 3-(4, 5-Dimethylthiazol-2-yl) 2, 5-diphe¬nyltetrazolium bromide (MTT) assay was used to analyze the effect of TCNS on cell proliferation. Light microscopic examination of giemsa solution stained cells was used to calculate the number of colonies with > 50 cells. Flow cytometry using a flow cytometer, while apoptosis detection kit were used to analyze induction of apoptosis.
Results: TCNS treatment significantly inhibited the viability of U138 NS and U138 AC cells in a concentration-dependent manner (p < 0.05). TCNS caused 86 % reduction in the capacity of U138 NS cells to form colonies and led to significant induction of apoptosis. The activation of caspase 3 and expression of Bax was increased significantly (p < 0.05). Moreover, TCNS treatment increased the median survival time of mice bearing glioma to 34 days compared to 22 days in untreated mice.
Conclusion: Thus, TCNS treatment significantly inhibits the viability of glioma cells and colony formation, but induces apoptosis and increases the median survival of mice. Hence, TCNS may be of therapeutic value for the treatment of glioma.
Keywords: Glioma, Tricyclic neovibsanin scaffold, Survival time, Colony formation, Apoptosis
